Metformin-Induced Glucagon-Like Peptide-1 Secretion Contributes to the Actions of Metformin in Type 2 Diabetes

Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action

Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274 · see citing works

Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies

Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238 · see citing works

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220 · see citing works

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · see citing works

Metformin—mode of action and clinical implications for diabetes and cancer

Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,345 · see citing works

Clinical pharmacokinetics of metformin

Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · see citing works

Mechanism by which metformin reduces glucose production in type 2 diabetes.

Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · see citing works

Identification of membrane-type receptor for bile acids (M-BAR)

Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02550-0 · Cited by 993 · see citing works

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

Shu, Y., Sheardown, S. A., Brown, C., Owen, R., Zhang, S., Castro, R. A., Ianculescu, A. G., Lin, Y., Lo, J. C.-M., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 963 · see citing works

Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance

Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 938 · see citing works

Farnesoid X receptor is essential for normal glucose homeostasis

Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 883 · see citing works

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

Miller, R., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 828 · see citing works

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738 · see citing works

Metformin and the gastrointestinal tract

McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · see citing works

Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance

Cauter, E. V., Mestrez, F., Sturis, J., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.3.368 · Cited by 643 · see citing works

The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion

Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · see citing works

Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563 · see citing works

The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions

Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · see citing works

Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus

Schvarcz, E., Palmer, M., Aman, J., Horowitz, M., Stridsberg, M., & Berne, C. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70080-5 · Cited by 416 · see citing works

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects

DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408 · see citing works

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369 · see citing works

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-Term Pharmacokinetic and 12-Week Dose-Ranging Studies

Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · see citing works

Accurate measurement of cholecystokinin in plasma

Rehfeld, J. F. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.5.991 · Cited by 320 · see citing works

Activation of p38 MAP kinase enhances sensitivity of muscle glucose transport to insulin

Geiger, P. C., Wright, D. C., Han, D., & Holloszy, J. O. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00477.2004 · Cited by 306 · see citing works

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 293 · see citing works

Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus

Napolitano, A., Miller, S. L., Nicholls, A. W., Baker, D., Horn, S. V., Thomas, E., Rajpal, D. K., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 285 · see citing works

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276 · see citing works

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265 · see citing works

Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin

Fisher, J. S., Gao, J., Han, D.-H., Holloszy, J. O., & Nolte, L. A. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2002.282.1.e18 · Cited by 244 · see citing works

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

Deane, A. M., Nguyen, N. Q., Stevens, J. E., Fraser, R. J., Holloway, R. H., Besanko, L. K., Burgstad, C. M., Jones, K. L., Chapman, M. J., Rayner, C. K., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1503 · Cited by 240 · see citing works

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

Migoya, E. M., Bergeron, R., Miller, J., Snyder, R., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 177 · see citing works

Evidence of Extrapancreatic Glucagon Secretion in Man

Lund, A., Bagger, J. I., Albrechtsen, N. J. W., Christensen, M., Grøndahl, M. F. G., Hartmann, B., Mathiesen, E. R., Hansen, C. P., Storkholm, J. H., van Hall, G., et al. (2015) · Diabetes · doi:10.2337/db15-1541 · Cited by 167 · see citing works

Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell

Mulherin, A. J., Oh, A., Kim, H., Grieco, A. J., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 158 · see citing works

Release of 5-Hydroxytryptamine From the Mucosa Is Not Required for the Generation or Propagation of Colonic Migrating Motor Complexes

Keating, D. J., & Spencer, N. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.020 · Cited by 154 · see citing works

Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine

Sun, E. W., de Fontgalland, D., Rabbitt, P., Hollington, P., Sposato, L., Due, S. L., Wattchow, D. A., Rayner, C. K., Deane, A. M., Young, R. L., et al. (2017) · Diabetes · doi:10.2337/db17-0058 · Cited by 152 · see citing works

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

Deacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 146 · see citing works

Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response

Becker, M. L., Visser, L. E., van Schaik, R. H. N., Albert Hofman, D., Uitterlinden, A. G., & Stricker, B. H. C. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328333bb11 · Cited by 139 · see citing works

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function

Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137 · see citing works

Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men

Geary, N., Kissileff, H. R., Pi-Sunyer, X., & Hinton, V. J. (1992) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1992.262.6.r975 · Cited by 134 · see citing works

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

DeFronzo, R. A., Buse, J. B., Kim, T., Burns, C. M., Skare, S., Baron, A., & Fineman, M. S. (2016) · Diabetologia · doi:10.1007/s00125-016-3992-6 · Cited by 131 · see citing works

Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes

Schwartz, S. L., Fonseca, V. A., Berner, B., Cramer, M., Chiang, Y.-K., & Lewin, A. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1967 · Cited by 129 · see citing works

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.

Mannucci, E., Tesi, F., Bardini, G., Ognibene, A., Mg, P., Ciani, S., Pezzatini, A., Brogi, M., Dicembrini, I., Cremasco, F., et al. (2004) · PubMed · Cited by 128 · see citing works

Effects of rectal administration of taurocholic acid on glucagon‐like peptide‐1 and peptide YY secretion in healthy humans

Wu, T., Bound, M. J., Standfield, S., Gedulin, B. R., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12043 · Cited by 124 · see citing works

The role of gut hormone peptide YY in energy and glucose homeostasis: Twelve years on

Manning, S., & Batterham, R. L. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170404 · Cited by 124 · see citing works

Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon.

Adrian, T. E., Ballantyne, G. H., Longo, W. E., Bilchik, A. J., Graham, S. E., Basson, M. D., Tierney, R. P., & Modlin, I. M. (1993) · Gut · doi:10.1136/gut.34.9.1219 · Cited by 115 · see citing works

The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera

Krarup, T., & Holst, J. J. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90005-3 · Cited by 110 · see citing works

The Effect of Intravenous Metformin on Glucose Metabolism During Hyperglycaemia in Type 2 Diabetes

Sum, C. ‐., Webster, J. M., Johnson, A. B., Catalano, C., Cooper, B. G., & Taylor, R. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01716.x · Cited by 103 · see citing works

Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus

Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 101 · see citing works

Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics

Medhus, A. W., Lofthus, C. M., Bredesen, J. E., & Husebye, E. (2001) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2001.00249.x · Cited by 99 · see citing works

Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon‐like peptide‐1 secretion

Hansen, M., Scheltema, M. J. V., Sonne, D. P., Hansen, J. S., Sperling, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12648 · Cited by 96 · see citing works

Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose

Vardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2013) · Diabetes · doi:10.2337/db13-0805 · Cited by 90 · see citing works

Mechanisms of metformin action on glucose transport and metabolism in human adipocytes

Grisouard, J., Timper, K., Radimerski, T., Frey, D. M., Peterli, R., Kola, B., Korbonits, M., Herrmann, P. C., Krähenbühl, S., Zulewski, H., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.021 · Cited by 80 · see citing works

Identification of unique release kinetics of serotonin from guinea‐pig and human enterochromaffin cells

Raghupathi, R., Duffield, M. D., Zelkas, L., Meedeniya, A. C. B., Brookes, S. J., Sia, T. C., Wattchow, D. A., Spencer, N. J., & Keating, D. J. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.259796 · Cited by 79 · see citing works

Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying

Nicolaus, M., Brödl, J., Linke, R., Woerle, H., Göke, B., & Schirra, J. R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0841 · Cited by 73 · see citing works

Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin

Bahne, E., Hansen, M., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12697 · Cited by 72 · see citing works

Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

Wu, T., Thazhath, S. S., Bound, M. J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.004 · Cited by 70 · see citing works

Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1

Sonne, D. P., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0309 · Cited by 65 · see citing works

Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects

Keller, J., Trautmann, M. E., Haber, H., Tham, L. S., Hunt, T., Mace, K., & Linnebjerg, H. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.005 · Cited by 61 · see citing works

Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in Type 2 diabetes mellitus

Koga, M., Otsuki, M., Kubo, M., Hashimoto, J., & Kasayama, S. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199808)15:8 · Cited by 58 · see citing works

Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study

Dujić, T., Zhou, K., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2016) · Diabetes Care · doi:10.2337/dc16-0706 · Cited by 56 · see citing works

Effect of Glucagon-like Peptide-1 Receptor Antagonism on Appetite and Food Intake in Healthy Men

Steinert, R. E., Schirra, J., Meyer-Gerspach, A. C., Kienle, P., Fischer, H., Schulte, F., Goeke, B., & Beglinger, C. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.083246 · Cited by 52 · see citing works

Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells

Krizhanovskii, C., Patrone, C., Holst, J. J., Zhang, Q., & Sjöholm, Å. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0637-5 · Cited by 51 · see citing works

Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography.

Miceli, J. N., Aravind, M. K., Cohen, S. N., & Done, A. K. (1979) · Clinical Chemistry · doi:10.1093/clinchem/25.6.1002 · Cited by 50 · see citing works

Effects of chronic treatment with metformin on dipeptidyl peptidase‐4 activity, glucagon‐like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

Thondam, S. K., Cross, A., Cuthbertson, D. J., Wilding, J. P. H., & Daousi, C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03675.x · Cited by 43 · see citing works

Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS)

Tsilchorozidou, T., Batterham, R. L., & Conway, G. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03285.x · Cited by 33 · see citing works

The antidiabetic gutsy role of metformin uncovered?

Burcelin, R. (2013) · Gut · doi:10.1136/gutjnl-2013-305370 · Cited by 26 · see citing works

Dose-Dependent Inhibition of Postprandial Gallbladder Motility and Plasma Hormone Secretion during Acute Hyperglycemia

Gielkens, H. A. J. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655298750026787 · Cited by 21 · see citing works

Relationship between gastric and gallbladder emptying and refilling in normal subjects and patients withH. pylori-positive and-negative idiopathic dyspepsia and correlation with symptoms

Marzio, L., Falcucci, M., Ciccaglione, A. F., Malatesta, M. G., Lapenna, D., Ballone, E., Antonelli, C., & Grossi, L. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02208580 · Cited by 19 · see citing works

Evolving Metformin Treatment Strategies in Type-2 Diabetes

Chacra, A. R. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f1bb · Cited by 18 · see citing works

GLP-1—A Candidate Humoral Mediator for Glucose Control After Roux-en-Y Gastric Bypass

Schirra, J. R. J., & Göke, B. (2014) · Diabetes · doi:10.2337/db13-1660 · Cited by 13 · see citing works

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686 · see citing works

GDF15 mediates the effects of metformin on body weight and energy balance

Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584 · see citing works

The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release

Martin, A. M., Sun, E. W. L., Rogers, G. B., & Keating, D. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00428 · Cited by 389 · see citing works

Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398 · see citing works

Systemic dysfunction and plasticity of the immune macroenvironment in cancer models

Allen, B. M., Hiam-Galvez, K. J., Burnett, C. E., Venida, A. C., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0892-6 · Cited by 316 · see citing works

A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan

Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278 · see citing works

Metformin: Is it a drug for all reasons and diseases?

Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R. S., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 282 · see citing works

The ever-changing roles of serotonin

Jones, L. A., Sun, E. W. L., Martin, A. M., & Keating, D. J. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105776 · Cited by 241 · see citing works

Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes

Milardi, D., Gazit, E., Radford, S. E., Xu, Y., Gallardo, R. U., Caflisch, A., Westermark, G. T., Westermark, P., Rosa, C. L., & Ramamoorthy, A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00981 · Cited by 199 · see citing works

Air−Liquid Interface Cultures of the Healthy and Diseased Human Respiratory Tract: Promises, Challenges, and Future Directions

Baldassi, D., Gabold, B., & Merkel, O. M. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000111 · Cited by 163 · see citing works

Metformin and Aging: A Review

Glossmann, H. H., & Lutz, O. M. D. (2019) · Gerontology · doi:10.1159/000502257 · Cited by 149 · see citing works

Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease

Xie, C., Huang, W., Young, R. L., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2021) · Nutrients · doi:10.3390/nu13041104 · Cited by 124 · see citing works

Metformin: Therapeutic profile in the treatment of type 2 diabetes

Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 131 · see citing works

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy

Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 114 · see citing works

Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy

van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 105 · see citing works

AMPK and the Endocrine Control of Metabolism

Townsend, L. K., & Steinberg, G. R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad012 · Cited by 107 · see citing works

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment

Yin, R., Xu, Y., Wang, X., Yang, L., & Zhao, D. (2022) · Molecules · doi:10.3390/molecules27103055 · Cited by 95 · see citing works

Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids

Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84 · see citing works

Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study

Bhansali, S., Bhansali, A. K., Dutta, P. R., Walia, R., & Dhawan, V. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14834 · Cited by 82 · see citing works

What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?

Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 79 · see citing works

Cell and tissue engineering in lymph nodes for cancer immunotherapy

Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 73 · see citing works

Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials

Benedetti, R., Benincasa, G., Glass, K., Chianese, U., Vietri, M. T., Congi, R., Altucci, L., & Claudio Napoli, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106039 · Cited by 75 · see citing works

Examining the clinical relevance of metformin as an antioxidant intervention

Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., & Adamska, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1330797 · Cited by 72 · see citing works

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

Schetters, S. T. T., Rodríguez, E., Kruijssen, L. J. W., Crommentuijn, M. H. W., Boon, L., den Bossche, J. V., den Haan, J. M. M., & van Kooyk, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000588 · Cited by 71 · see citing works

The Mechanism of Action of Biguanides: New Answers to a Complex Question

Magno, L. D., Pastena, F. D., Bordone, R., Coni, S., & Canettieri, G. (2022) · Cancers · doi:10.3390/cancers14133220 · Cited by 75 · see citing works

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Froldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 68 · see citing works

Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes

Mashayekhi, M., Nian, H., Mayfield, D., Devin, J. K., Gamboa, J. L., Yu, C., Silver, H. J., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes · doi:10.2337/db23-0356 · Cited by 67 · see citing works

Understanding the action mechanisms of metformin in the gastrointestinal tract

Cheng, M., Ren, L., Jia, X., Wang, J., & Cong, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1347047 · Cited by 70 · see citing works

Increased hepatic gluconeogenesis and type 2 diabetes mellitus

Barroso, E., Jurado-Aguilar, J., Wahli, W., Palomer, X., & Vázquez‐Carrera, M. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.006 · Cited by 66 · see citing works

The role of endogenous GIP and GLP-1 in postprandial bone homeostasis

Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., ROSENKILDE, M. M., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115553 · Cited by 61 · see citing works

The composition of the gut microbiota following early-life antibiotic exposure affects host health and longevity in later life

Lynn, M. A., Eden, G. L., Ryan, F. J., Bensalem, J., Wang, X., Blake, S. J., Choo, J. M., Tee, Y. C., Sribnaia, A., James, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109564 · Cited by 61 · see citing works

Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review

Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62 · see citing works

Pharmacology of metformin – An update

Glossmann, H. H., & Lutz, O. M. D. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172782 · Cited by 61 · see citing works

Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection

Michlmayr, D., Kim, E., Rahman, A. H., Raghunathan, R. R., Kim‐Schulze, S., Che, Y., Kalaycı, S., Gumus, Z. H., Kuan, G. M., Balmaseda, Á., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107569 · Cited by 51 · see citing works

Effects of different doses of exercise and diet-induced weight loss on beta-cell function in type 2 diabetes (DOSE-EX): a randomized clinical trial

Legaard, G. E., Lyngbæk, M. P. P., Almdal, T., Karstoft, K., Bennetsen, S. L., Feineis, C. S., Nielsen, N. S., Durrer, C. G., Liebetrau, B., Nystrup, U., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00799-7 · Cited by 55 · see citing works

Research progress on the relationship between bile acid metabolism and type 2 diabetes mellitus

Hou, Y., Zhai, X., Wang, X., Wu, Y., Wang, H., Qin, Y., Han, J., & Meng, Y. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01207-6 · Cited by 55 · see citing works

Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence

Vessoni, A. T., Filippi‐Chiela, E. C., Lenz, G., & Batista, L. F. Z. (2019) · Oncogene · doi:10.1038/s41388-019-1128-4 · Cited by 54 · see citing works

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy

Liu, Y., Afzal, J. M., Vakrou, S., Greenland, G. V., Talbot, C. C., Hebl, V. B., Guan, Y., Karmali, R., Tardiff, J. C., Leinwand, L. A., et al. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00170 · Cited by 48 · see citing works

Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia

Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15030312 · Cited by 48 · see citing works

Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis

Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa074 · Cited by 37 · see citing works

Mitochondrial AIF loss causes metabolic reprogramming, caspase-independent cell death blockade, embryonic lethality, and perinatal hydrocephalus

Delavallée, L., Mathiah, N., Cabon, L., Mazeraud, A., Brunelle-Navas, M.-N., Lerner, L. K., Tannoury, M., Prola, A., Moreno‐Loshuertos, R., Baritaud, M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101027 · Cited by 32 · see citing works

Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats

Dik, B., Coşkun, D., Bahçıvan, E., & Üney, K. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-38 · Cited by 32 · see citing works

Metformin: From diabetes to cancer to prolongation of life

Sirtori, C. R., Castiglione, S., & Pavanello, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107367 · Cited by 33 · see citing works

The Potential Therapeutic Role of Metformin in Diabetic and Non-Diabetic Bone Impairment

Mu, W., Liang, G., Feng, Y., Jiang, Y., & Qu, F. (2022) · Pharmaceuticals · doi:10.3390/ph15101274 · Cited by 30 · see citing works

Myeloid-Derived Growth Factor Promotes Intestinal Glucagon-Like Peptide-1 Production in Male Mice With Type 2 Diabetes

Wang, L., Li, Y., Guo, B., Zhang, J., Zhu, B., Li, H., Ding, Y., Meng, B., Zhao, H., Xiang, L., et al. (2020) · Endocrinology · doi:10.1210/endocr/bqaa003 · Cited by 31 · see citing works

Labyrinthopeptin A1 inhibits dengue and Zika virus infection by interfering with the viral phospholipid membrane

Oeyen, M., Meyen, E., Noppen, S., Claes, S., Doijen, J., Vermeire, K., Süßmuth, R. D., & Schols, D. (2021) · Virology · doi:10.1016/j.virol.2021.07.003 · Cited by 29 · see citing works

Hyperglycemia induces NF‐κB activation and MCP‐1 expression via downregulating GLP‐1R expression in rat mesangial cells: inhibition by metformin

Kang, Z., Zeng, J., Zhang, T., Lin, S., Gao, J., Jiang, C., Fan, R., & Yin, D. (2019) · Cell Biology International · doi:10.1002/cbin.11184 · Cited by 28 · see citing works

Exendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review

Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 27 · see citing works

The Hormetic Effect of Metformin: “Less Is More”?

Panfoli, I., Puddu, A., Bertola, N., Ravera, S., & Maggi, D. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126297 · Cited by 27 · see citing works

Metformin treatment for 8 days impacts multiple intestinal parameters in high-fat high-sucrose fed mice

Bravard, A., Gérard, C., Defois, C., Benoit, B., Makki, K., Meugnier, E., Rainteau, D. P., Rieusset, J., Godet, M., & Vidal, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-95117-0 · Cited by 27 · see citing works

Metformin-mediated epigenetic modifications in diabetes and associated conditions: Biological and clinical relevance

Giordo, R., Posadino, A. M., Mangoni, A. A., & Pintus, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115732 · Cited by 27 · see citing works

From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease

Poznyak, A. V., Litvinova, L. S., Poggio, P., Moschetta, D., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179738 · Cited by 25 · see citing works

A Single Dose of Oral Metformin Reduces the Post-Prandial Glucose Response Through a Transient Modulation of Apical Sodium-Glucose Co-Transporter

Zubiaga, L., Briand, O., Auger, F., Touche, V., Hübert, T., Thévenet, J., Marciniak, C., Quenon, A., Bonner, C., Peschard, S., et al. (2019) · iScience · doi:10.1016/j.isci.2023.106057 · Cited by 23 · see citing works

Metformin in Gestational Diabetes Mellitus: To Use or Not to Use, That Is the Question

Tocci, V., Mirabelli, M., Salatino, A., Sicilia, L., Giuliano, S., Brunetti, F. S., CHIEFARI, E. D., Sarro, G. D., FOTI, D. P., & Brunetti, A. (2023) · Pharmaceuticals · doi:10.3390/ph16091318 · Cited by 31 · see citing works

Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?

Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 23 · see citing works

Metformin triggers PYY secretion in human gut mucosa

Sun, E. W. L., Martin, A. M., Wattchow, D. A., DeFontgalland, D., Rabbitt, P., Hollington, P., Young, R. L., & Keating, D. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02460 · Cited by 23 · see citing works

A Planar Culture Model of Human Absorptive Enterocytes Reveals Metformin Increases Fatty Acid Oxidation and Export

Gomez-Martinez, I., Bliton, R. J., Breau, K. A., Czerwinski, M. J., Williamson, I., Wen, J., Rawls, J. F., & Magness, S. T. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.04.009 · Cited by 22 · see citing works

Examining the predictive accuracy of metabolomics for small-for-gestational-age babies: a systematic review

Leite, D. F. B., Morillon, A.-C., Junior, E. F. D. M., Souza, R. T., McCarthy, F. P., Khashan, A. S., Baker, P. N., Kenny, L. C., & Cecatti, J. G. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031238 · Cited by 22 · see citing works

Management of Diabetes in Patients Undergoing Bariatric Surgery

Mulla, C. M., Baloch, H. M., & Hafida, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1242-2 · Cited by 23 · see citing works

Alterations in GLP-1 and PYY release with aging and body mass in the human gut

Jones, L. A., Sun, E. W. L., Lumsden, A. L., Thorpe, D. W., Peterson, R. A., de Fontgalland, D., Sposato, L., Rabbitt, P., Hollington, P., Wattchow, D. A., et al. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112072 · Cited by 21 · see citing works

Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery

Sari, C., Seip, R. L., & Umashanker, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.588016 · Cited by 20 · see citing works

Stimulatory effect of imeglimin on incretin secretion

Yingyue, Q., Sugawara, K., Takahashi, H., Yokoi, N., Ohbayashi, K., Iwasaki, Y., Seino, S., & Ogawa, W. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14001 · Cited by 20 · see citing works

Gut–adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?

Silva, D., & Matafome, P. N. (2020) · Obesity Reviews · doi:10.1111/obr.13130 · Cited by 20 · see citing works

Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment

Lok, K.-H., Wareham, N. J., Nair, R. S., How, C. W., & Chuah, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106237 · Cited by 19 · see citing works

Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study

Xie, C., Iroga, P. E., Bound, M. J., Grivell, J., Huang, W., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2024) · Diabetologia · doi:10.1007/s00125-024-06131-6 · Cited by 21 · see citing works

Povidone iodine treatment is deleterious to human ocular surface conjunctival cells in culture

Swift, W., Bair, J. A., Chen, W., Li, M., Lie, S., Li, D., Yang, M., Shatos, M. A., Hodges, R. R., Kolko, M., et al. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000545 · Cited by 18 · see citing works

Metformin: A Promising Antidiabetic Medication for Cancer Treatment

Mu, W., Jiang, Y., Liang, G., Feng, Y., & Qu, F. (2022) · Current Drug Targets · doi:10.2174/1389450124666221104094918 · Cited by 18 · see citing works

Treatment of type 2 diabetes mellitus in the elderly – Special considerations

Gadó, K., Tabák, Á. G., Vingender, I., Domján, G., & Dörnyei, G. (2024) · Physiology International · doi:10.1556/2060.2024.00317 · Cited by 21 · see citing works

Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer

Bora, V. R., & Patel, B. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119329 · Cited by 18 · see citing works

Metformin action in the gut―insight provided by [18F]FDG PET imaging

Tsuchida, H., Morita, Y., Nogami, M., & Ogawa, W. (2021) · Diabetology International · doi:10.1007/s13340-021-00545-y · Cited by 16 · see citing works

Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies

Watkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 18 · see citing works

Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control

Sebo, Z. L., Chakrabarty, R. P., Grant, R. A., D’Alessandro, K. B., Koss, A. R., Blum, J. L. E., Davidson, S. M., Reczek, C. R., & Chandel, N. S. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01530-y · Cited by 21 · see citing works

Is metformin a geroprotector? A peek into the current clinical and experimental data

Zajda, A., Huttunen, K. M., Sikora, J., Podsiedlik, M., & Markowicz-Piasecka, M. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111350 · Cited by 16 · see citing works

Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations

Sarnobat, D., Moffett, R. C., Flatt, P. R., & Tarasov, A. I. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01620-6 · Cited by 16 · see citing works

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension

Borg, M. J., Xie, C., Rayner, C. K., Horowitz, M., Jones, K. L., & Wu, T. (2021) · Nutrients · doi:10.3390/nu13082826 · Cited by 15 · see citing works

Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes

Cravalho, C. K. L., Meyers, A. G., Mabundo, L. S., Courville, A. B., Yang, S. B., Cai, H., Dai, Y., Walter, M. F., Walter, P. J., Sharma, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05236-y · Cited by 15 · see citing works

Dihydromyricetin promotes GLP-1 release and glucose uptake by STC-1 cells and enhances the effects of metformin upon STC-1 cells and diabetic mouse model

Yao, Y., Li, X., Yang, X., Mou, H., & Wei, L. (2023) · Tissue and Cell · doi:10.1016/j.tice.2023.102108 · Cited by 14 · see citing works

Striking a gut–liver balance for the antidiabetic effects of metformin

Barroso, E., Montori-Grau, M., Wahli, W., Palomer, X., & Vázquez‐Carrera, M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.004 · Cited by 14 · see citing works

Deep-learning on-chip light-sheet microscopy enabling video-rate volumetric imaging of dynamic biological specimens

Chen, X., Ping, J., Sun, Y., Yi, C., Liu, S., Gong, Z., & Fei, P. (2021) · Lab on a Chip · doi:10.1039/d1lc00475a · Cited by 14 · see citing works

Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial

Cesar, T. B., de Oliveira, M. R. M., Sandrim, V. C., Mendes, A., Bruder, R., de Oliveira, R. A. A., Sivieri, K., & Milenković, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1639901 · Cited by 13 · see citing works

Metformin Effects on SHIP2, AMPKs and Gut Microbiota: Recent Updates on Pharmacology

Shivaprakash, P., Beeraka, N. M., Madhunapantula, S. V., Nikolenko, V. N., & Basalingappa, K. M. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673289342240213040144 · Cited by 13 · see citing works

Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial

Usui, R., Hamamoto, Y., Imura, M., Omori, Y., Yamazaki, Y., Kuwata, H., Tatsuoka, H., Shimomura, K., Murotani, K., Yamada, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16086 · Cited by 13 · see citing works

The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity

Pillai, A. A., Melo, L., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000832 · Cited by 13 · see citing works

Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin

Borg, M. J., Rayner, C. K., Jones, K. L., Horowitz, M., Xie, C., & Wu, T. (2020) · Pharmaceuticals · doi:10.3390/ph13110410 · Cited by 15 · see citing works

CD14+monocytes are the main leucocytic sources of CXCL10 in response toPlasmodium falciparum

Ioannidis, L. J., Eriksson, E. M., & Hansen, D. S. (2019) · Parasitology · doi:10.1017/s0031182019001744 · Cited by 13 · see citing works

Chemosensing in enteroendocrine cells: mechanisms and therapeutic opportunities

Yang, M. H., Reimann, F. M., & Gribble, F. M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000614 · Cited by 12 · see citing works

Evidence for Glucagon Secretion and Function Within the Human Gut

Sun, E. W. L., Martin, A. M., de Fontgalland, D., Sposato, L., Rabbitt, P., Hollington, P., Wattchow, D. A., Colella, A. D., Chataway, T., Albrechtsen, N. J. W., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab022 · Cited by 12 · see citing works

Metformin increases the uptake of glucose into the gut from the circulation in high-fat diet-fed male mice, which is enhanced by a reduction in whole-body Slc2a2 expression

Morrice, N., Vainio, S., Mikkola, K., van Aalten, L., Gallagher, J. R., Ashford, M. L. J., McNeilly, A. D., McCrimmon, R. J., Grosfeld, A., Serradas, P., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101807 · Cited by 12 · see citing works

Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions

Jones, M., Ionescu, C. M., Walker, D., Wagle, S. R., Kovačević, B., Chester, J., Foster, T., Johnston, E., Kuthubutheen, J., Brown, D. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020836 · Cited by 13 · see citing works

Cellular mechanism of diabetes remission by bariatric surgery

Ye, J., Hu, Y.-X., Wang, C., Lian, H., & Dong, Z. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.07.001 · Cited by 11 · see citing works

Combining a diet rich in fermentable carbohydrates with metformin improves glycaemic control and reshapes the gut microbiota in people with prediabetes

Chu, N. H. S., Ling, J., Poon, E. W. M., Lee, J. Y. S., Song, Q., Zuo, Z., Muir, J. G., Chan, J. C. N., & Chow, E. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01336-4 · Cited by 11 · see citing works

Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review

Alfaraidi, H., & Samaan, M. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1072879 · Cited by 11 · see citing works

Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease

Greco, M., Munir, A., Musarò, D., Coppola, C., & Maffia, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1244022 · Cited by 10 · see citing works

Exploring the recent advancements and future prospects of personalized medicine in type 2 diabetes

Nameghi, S. M. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100193 · Cited by 14 · see citing works

Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance

Brīvība, M., Silamiķele, L., Kalniņa, I., Silamiķelis, I., Birzniece, L., Ansone, L., Jagare, L., Elbere, I., & Kloviņš, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1232143 · Cited by 10 · see citing works

Treatment of type 2 diabetes in children: what are the specific considerations?

Grøndahl, M. F. G., Johannesen, J., Kristensen, K., & Knop, F. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1954160 · Cited by 12 · see citing works

Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis

Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9 · see citing works

Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes

Attaye, I., Witjes, J. J., Koopen, A. M., van der Vossen, E. W. J., Zwirs, D., Wortelboer, K., Collard, D., Kemper, E. M., Winkelmeijer, M., Holst, J. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110455 · Cited by 9 · see citing works

Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA»

Dedov, I. I., Romantsova, T. I., & Shestakova, M. V. (2019) · Obesity and metabolism · doi:10.14341/omet10076 · Cited by 9 · see citing works

Intestinal TGR5-targeted carrier-drug conjugate improves glycemic control in mice and pigs

Zhang, Y., Huang, H., Wang, Y., Li, X., Hou, P., Yu, M., Zhang, Z., Guo, S., Liu, C., Zhang, Z., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado5177 · Cited by 8 · see citing works

The Role of Glucagon-Like Peptide-1 for the Postprandial Effects of Metformin in Type 2 Diabetes

Hansen, L. S., Gasbjerg, L. S., Brønden, A., Dalsgaard, N. B., Bahne, E., Sørensen, P. H., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2018) · Diabetes · doi:10.2337/db18-1969-p

The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial

Hansen, L. S., Gasbjerg, L. S., Brønden, A., Dalsgaard, N. B., Bahne, E., Stensen, S., Hellmann, P. H., Rehfeld, J. F., Hartmann, B., Albrechtsen, N. J. W., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae095 · Cited by 6 · see citing works

Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin

Bahne, E., Hansen, M., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12697 · Cited by 72 · see citing works

Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell

Mulherin, A. J., Oh, A., Kim, H., Grieco, A. J., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 158 · see citing works

Addition of metformin to exogenous glucagon-like peptide–1 results in increased serum glucagon-like peptide–1 concentrations and greater glucose lowering in type 2 diabetes mellitus

Cuthbertson, J., Patterson, S., O'Harte, F. P. M., & Bell, P. M. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.001 · Cited by 54 · see citing works